Exposure-efficacy relationship of trastuzumab emtansine (T-DM1) in EMILIA, a phase III study of T-DM1 versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC)

被引：0
|
作者：
Wang, Bei
Jin, Jin
Wada, Russell
Fang, Liang
Lu, Dan
Guardino, Ellie
Swain, Sandra M.
Untch, Michael
Girish, Sandhya
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Quantitat Solut, Menlo Pk, CA USA
[3] Medstar Washington Hosp Ctr, Washington, DC USA
[4] HELIOS Hosp Berlin Buch, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
644
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.
    Pegram, Mark D.
    Blackwell, Kimberly
    Miles, David
    Bianchi, Giulia Valeria
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Olsen, Steven R.
    Fang, Liang
    Lu, Michael
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [2] Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.
    Blackwell, Kimberly L.
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark D.
    Do-Youn Oh
    Dieras, Veronique
    Olsen, Steven R.
    Fang, Liang
    Lu, Michael W.
    Guardino, Ellie
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Exposure-safety relationship of trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC)
    Jin, Jin
    Wang, Bei
    Gao, Yuying
    Samant, Meghan
    Li, Chunze
    Song, Chunyan
    Swain, Sandra M.
    Untch, Michael
    Girish, Sandhya
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC).
    Baselga, Jose
    Verma, Sunil
    Ro, Jungsil
    Huober, Jens
    Guardino, Ellie
    Fang, Liang
    Olsen, Steven
    Phillips, Gail Lewis
    de Haas, Sanne
    Pegram, Mark
    CANCER RESEARCH, 2013, 73 (08)
  • [5] Trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer
    Thibault, C.
    ONCOLOGIE, 2013, 15 (02) : 126 - 127
  • [6] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
    Boyraz, Baris
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Roach, Emir C.
    Kizilarslanoglu, Muhammet C.
    Petekkaya, Ibrahim
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
  • [7] Trastuzumab emtansine (T-DM1) for the treatment of HER2-positive breast cancer
    Sliwkowski, Mark X.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [8] Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): Data from the phase III EMILIA study
    Im, S-A.
    Park, I.
    Sohn, J. H.
    Im, Y-H.
    Lee, S. C.
    Chang, H-K.
    Macharia, H.
    Sun, G.
    Lamour, F.
    Oh, D-Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S488 - S489
  • [9] Metastatic HER2-positive Breast Cancer New Perspectives with Trastuzumab Emtansine (T-DM1)
    Satzger, Ulla
    ONKOLOGIE, 2013, 36 (09): : 525 - 525
  • [10] PATIENT-REPORTED OUTCOMES (PROS) FROM EMILIA, A PHASE 3 STUDY OF TRASTUZUMAB EMTANSINE (T-DM1) VS CAPECITABINE AND LAPATINIB (XL) IN HER2-POSITIVE LOCALLY ADVANCED OR MBC
    Welslau, M.
    Dieras, V.
    Sohn, J.
    Hurvitz, S.
    Lalla, D.
    Fang, L.
    Guardino, E.
    Miles, D.
    ANNALS OF ONCOLOGY, 2012, 23 : 120 - 120
12345